Efficacy of Neoadjuvant Single or Dual Anti-HER-2 Therapy Combined with Chemotherapy in Patients with HER-2-Positive Breast Cancer: A Single-Center Retrospective Study

BACKGROUND: Studies have shown that neoadjuvant anti-HER-2 therapy and chemotherapy can increase pathologic complete response (pCR) rate in HER-2-positive breast cancer patients and improve prognosis. However, data from Chinese patients are limited. Therefore, we conducted a single-center retrospect...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Qian, Li, Jia-Yi, Ren, Qing-Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408383/
https://www.ncbi.nlm.nih.gov/pubmed/34048175
http://dx.doi.org/10.31557/APJCP.2021.22.5.1467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8408383/
https://www.ncbi.nlm.nih.gov/pubmed/34048175
http://dx.doi.org/10.31557/APJCP.2021.22.5.1467

Ejemplares similares